www.fdanews.com/articles/62466-bristol-myers-squibb-company-and-medivir-ab-announce-worldwide-collaboration-to-develop-and-commercialize-miv-170-for-the-treatment-of-hiv-1-infection-in-adults
BRISTOL-MYERS SQUIBB COMPANY AND MEDIVIR AB ANNOUNCE WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE MIV-170 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS
September 13, 2006
Bristol-Myers Squibb Company and Medivir AB announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=29794&full=1)